<DOC>
	<DOC>NCT01012219</DOC>
	<brief_summary>This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary hypercholesterolemia or mixed dyslipidemia. Period 3 will be open-label and will evaluate single dose pharmacokinetics of nicotinic acid and laropiprant components of Tredaptive.</brief_summary>
	<brief_title>A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipidemia, Familial Combined</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<criteria>Participant has primary hypercholesterolemia or mixed dyslipidemia (high cholesterol) Participant is a nonsmoker Participant has a history of chronic seizures Participant has a history of cancer Participant has a history of stomach or intestinal ulcers or any history of GI bleeding Participant has had major surgery, donated blood or participated in another investigational study in the past 4 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>